公开(公告)号：ID23421A

公开(公告)日：2000-04-20

申请号：ID991496

申请日：1998-05-28

Applicant: BASF AG

Inventor： STEINER GERD ,  DULLWEBER UTA ,  STARK DOROTHEA ,  BACH ALFRED

IPC: A61K31/495 ,  A61K31/519 ,  A61P25/00 ,  A61P25/24 ,  A61P43/00 ,  C07D495/04 ,  C07D495/05 ,  A62K31/495

Abstract: PCT No. PCT/EP98/03230 Sec. 371 Date Dec. 6, 1999 Sec. 102(e) Date Dec. 6, 1999 PCT Filed May 29, 1998 PCT Pub. No. WO98/56792 PCT Pub. Date Dec. 17, 19983-Substituted 3,4-dihydrothieno[2,3-d]pyrimidine derivatives of the formula I where R1 and R2 are a hydrogen atom or a C1-C4-alkyl group, R3 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which may be fused to a benzene nucleus which may be unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, hydroxyl, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups, and may contain 1 nitrogen atom, or to a 5- or 6-membered ring, which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, it being possible for the linkage between Y and Z also to be a double bond, and n is 2, 3 or 4, and the physiologically tolerated salts thereof.

公开(公告)号：ID24839A

公开(公告)日：2000-08-24

申请号：ID991726

申请日：1998-07-03

Applicant: BASF AG

Inventor： STARK DOROTHEA ,  BLANK STEFAN ,  TREIBER HANS-JORG ,  UNGER LILIANE

IPC: A61K31/33 ,  A61K31/41 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/506 ,  A61K31/53 ,  A61K31/551 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P43/00 ,  C07D249/08 ,  C07D249/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

Abstract: Triazole compounds of the following formula:where Ar1, A, B and Ar2 have the meanings given in the description, possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to dopamine D3 ligands.